Worcester, USA - 25 Sep `19Dermavant Sciences: Cerdulatinib Gel

Official Title: A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo. 

In Brief: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks

Ages Eligible:  18 Years to 70 Years

Start Date: September 25, 2019

Completion Date (estimated): July 2020

Status: Active, recruiting

Study ID

  • ClinicalTrials.gov: NCT04103060
  • Other Study ID Numbers: DMVT-502-2101

Location: Dermavant Investigational Site: Worcester, Massachusetts, United States, 01605

Contact: To learn more about this study, you or your doctor may contact Dermavant Sciences by phone +1-480-666-0844 or email dermavantclinicaltrials@dermavant.com. Please refer to this study by its ClinicalTrials.gov identifier (NCT number)

FAQOther Questions

  • Who is prone to vitiligo?

    Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...

  • Shall I take vitamin D for my vitiligo?

    In Brief Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be id...

  • Is it Bitiligo? Vitaligo? Veteligo?

    There are so many different ways that people try and spell or even pronounce Vitiligo.  Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vita...